Focus Stocks
Integra LifeSciences Announces Launch of New Jarit(R) Take-Apart Laparoscopic Instruments
Published on Monday, 26 March 2012 06:10 Written by TradersHuddle Staff
PLAINSBORO, N.J., March 26, 2012 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its new line of Jarit® Take-Apart Laparoscopic instruments. The new instruments allow the components to be fully disassembled, making cleaning and visual inspection easier. Integra will feature the Jarit® Take-Apart Laparoscopic instruments at the 59th Congress of the Association of periOperative Registered Nurses (AORN), March 24-29, 2012, in New Orleans, Louisiana.
This product line addresses the growing concerns of both hospitals and regulatory bodies about the need for instruments that can be more easily cleaned and sterilized. Integra has recently introduced numerous products to enable hospitals to increase the certainty of using clean instruments on every patient. Adding features that increase the ease and visual verification of cleaning are expected to further limit uncertainty for OR personnel.
"These new laparoscopic patterns are an important addition to our instrument portfolio. Long, narrow cannulas and intricately fitting components are a challenge to clean, yet are necessary for minimally invasive surgery. Our new take-apart design balances ease of cleaning with surgeon preference, both of which are important goals in achieving optimal patient care," said Dan Reuvers, President, Integra Surgical.
Integra is a leading provider of surgical instruments used in general surgery, neurosurgery, cardiac surgery and most other surgical modalities, as well as surgical retractor systems and illumination products. Integra's brands include recognized names like Luxtec®, Jarit®, Miltex®, Ruggles®, and Omni-Tract®.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use the products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2011 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Gianna Sabella
Director of Corporate Communications
(609) 936-2389
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Related Articles
- Integra LifeSciences to Host Its First Quarter 2013 Earnings Results Conference Call on May 2, 2013
- Integra LifeSciences Issues Voluntary Recall of Certain Products Manufactured in its Anasco, Puerto Rico Facility
- Integra LifeSciences Integra(R) IPP-ON(R) PIP Fusion System Surpasses 4,000 Hammertoe Correction Implants
- Integra LifeSciences Expands Its Product Offering for Spinal Deformity
- Integra LifeSciences Expands Shoulder Product Line With the Introduction of a Proximal Humeral Fracture Plate System
- Integra LifeSciences Holdings Corporation Announces Changes to Its Board of Directors
- Integra LifeSciences to Participate in Investor Conferences in March
- Integra LifeSciences Reports Fourth Quarter 2012 Financial Results
- Integra LifeSciences to Participate in Investor Conferences in February
- Integra LifeSciences Receives Warning Letter in Anasco, Puerto Rico, Manufacturing Facility
Related Partner Headlines
- Integra LifeSciences Announces Contract With aap Implantate AG to Provide Stainless Headed Compression Screws for Mid and Hindfoot Reconstruction - Benzinga
- Integra LifeSciences Holdings Inc. Stock Upgraded (IART) - TheStreet.com
- Barrington Research Reiterates Integra LifeSciences Outperform, $50 PT - Benzinga
- UPDATE: Citigroup Raises Target to $36 on Integra Lifesciences Holdings - Benzinga
- Integra LifeSciences Stock Hits New 52-Week Low (IART) - TheStreet.com
- Vical, RF Micro: After-Hours Trading - TheStreet.com
- Integra LifeSciences Stock Falls On Unusually High Volume (IART) - TheStreet.com
- Integra LifeSciences Stock Hits New 52-Week Low (IART) - TheStreet.com
- Integra LifeSciences Stock Hits New 52-Week Low (IART) - TheStreet.com
- Integra LifeSciences Stock Hits New 52-Week Low (IART) - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,345.49 Trade time:10:54AM EDT Value change:▼8.91 (-0.06%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,667.44 Trade time:10:54AM EDT Value change:▼0.03 (0.00%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,499.39 Trade time:10:54AM EDT Value change:▲0.42 (0.01%)In The Wires
-
Lighting Science® Introduces Innovative Lighting at the 2013 IPI Conference and Expo -
VASCO Announces Acquisition of Cronto (United Kingdom) -
AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy -
Platts: Asia Spot LNG Prices for June Delivery Fall 5.8% on Weak Demand -
Sears Holdings To Hold Fiscal 2013 First Quarter Earnings Analyst And Investor Conference Call And Audio Webcast -
blu eCigs Announces Sponsorship of Sasquatch! Music Festival -
Dominion Resources Black Warrior Trust Announces 2nd Quarter Cash Distribution and 2013 Reserve Quantities -
AT&T Hiring More Than 120 In South Carolina








